Onivyde

Department of Health written question – answered on 24th March 2017.

Alert me about debates like this

Photo of David Simpson David Simpson Shadow DUP Spokesperson (Business, Innovation and Skills), Shadow DUP Spokesperson (Environment, Food and Rural Affairs)

To ask the Secretary of State for Health, when he expects a decision to be made on approval of the Onivyd drug for NHS use in the treatment of pancreatic cancer.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

The National Institute for Health and Care Excellence currently expects to publish final guidance on the use of Onivyde (pegylated liposomal irinotecan) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy in April 2017.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.